Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIR NASDAQ:CADL NASDAQ:RNAC NYSE:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.14-0.8%$3.54$2.45▼$4.14$248.79M0.24373,460 shs116,376 shsCADLCandel Therapeutics$4.86-2.3%$5.99$3.79▼$14.60$266.81M-0.91.02 million shs407,006 shsRNACCartesian Therapeutics$9.96-1.3%$11.66$8.46▼$26.50$258.57M0.3978,780 shs32,035 shsVNRXVolitionRx$0.64+0.6%$0.68$0.40▼$0.94$69.29M1.27198,701 shs134,071 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-2.77%-7.06%-6.51%-0.32%-13.90%CADLCandel Therapeutics-2.55%-15.19%-17.44%-8.97%-22.83%RNACCartesian Therapeutics-0.98%+2.54%-4.18%-3.07%-23.09%VNRXVolitionRx+4.26%-3.95%-0.78%+13.26%-2.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.14-0.8%$3.54$2.45▼$4.14$248.79M0.24373,460 shs116,376 shsCADLCandel Therapeutics$4.86-2.3%$5.99$3.79▼$14.60$266.81M-0.91.02 million shs407,006 shsRNACCartesian Therapeutics$9.96-1.3%$11.66$8.46▼$26.50$258.57M0.3978,780 shs32,035 shsVNRXVolitionRx$0.64+0.6%$0.68$0.40▼$0.94$69.29M1.27198,701 shs134,071 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-2.77%-7.06%-6.51%-0.32%-13.90%CADLCandel Therapeutics-2.55%-15.19%-17.44%-8.97%-22.83%RNACCartesian Therapeutics-0.98%+2.54%-4.18%-3.07%-23.09%VNRXVolitionRx+4.26%-3.95%-0.78%+13.26%-2.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0091.39% UpsideCADLCandel Therapeutics 3.00Buy$20.00311.86% UpsideRNACCartesian Therapeutics 2.80Moderate Buy$40.00301.81% UpsideVNRXVolitionRx 3.00Buy$3.50446.02% UpsideCurrent Analyst Ratings BreakdownLatest VNRX, RNAC, CADL, and AVIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/3/2025CADLCandel TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.00 ➝ $7.008/15/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/17/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/9/2025CADLCandel TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/9/2025RNACCartesian TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$38.007/9/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$23.006/10/2025VNRXVolitionRxJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$3.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/ACADLCandel Therapeutics$120K2,221.62N/AN/A$1.41 per share3.44RNACCartesian Therapeutics$38.91M6.65N/AN/A($0.27) per share-36.87VNRXVolitionRx$1.32M52.28N/AN/A($0.11) per share-5.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)CADLCandel Therapeutics-$55.18M-$0.69N/AN/AN/AN/A-41.00%-26.81%11/13/2025 (Estimated)RNACCartesian Therapeutics-$77.42M-$52.83N/AN/AN/AN/AN/A-6.36%11/6/2025 (Estimated)VNRXVolitionRx-$35.32M-$0.25N/A∞N/A-2,321.14%N/A-163.39%N/ALatest VNRX, RNAC, CADL, and AVIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CADLCandel Therapeutics-$0.17-$0.09+$0.08-$0.09N/AN/A8/7/2025Q2 2025AVIRAtea Pharmaceuticals-$0.46-$0.44+$0.02-$0.44N/AN/A8/7/2025Q2 2025RNACCartesian Therapeutics-$0.76$0.50+$1.26$0.50$0.77 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.1719.17CADLCandel Therapeutics0.017.047.04RNACCartesian TherapeuticsN/A13.3313.33VNRXVolitionRxN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%CADLCandel Therapeutics13.93%RNACCartesian Therapeutics86.95%VNRXVolitionRx8.09%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%CADLCandel Therapeutics16.60%RNACCartesian Therapeutics60.30%VNRXVolitionRx10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7079.36 million64.99 millionOptionableCADLCandel Therapeutics6054.90 million45.78 millionOptionableRNACCartesian Therapeutics6426.00 million10.32 millionOptionableVNRXVolitionRx80107.60 million80.80 millionOptionableVNRX, RNAC, CADL, and AVIR HeadlinesRecent News About These CompaniesVolitionRx signs first human out licensing deal for APSSeptember 9 at 1:31 PM | msn.comVolition Signs First Human Out Licensing DealSeptember 9 at 8:45 AM | prnewswire.comZacks Small Cap Estimates VolitionRx Q3 EarningsAugust 29, 2025 | marketbeat.comQ3 Earnings Forecast for VolitionRx Issued By HC WainwrightAugust 22, 2025 | marketbeat.comHC Wainwright Has Negative Outlook of VolitionRx Q4 EarningsAugust 21, 2025 | marketbeat.comVolitionRx Limited (AMEX:VNRX) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comVolitionRx Limited (VNRX) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | seekingalpha.comVolitionRx reports Q2 revenue $400K, consensus $375.72KAugust 14, 2025 | msn.comVolitionRx Limited Announces Second Quarter 2025 Financial Results and Business UpdateAugust 14, 2025 | prnewswire.comInsights into VolitionRX's Upcoming EarningsAugust 14, 2025 | benzinga.comVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update | ...August 8, 2025 | gurufocus.comVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business UpdateAugust 8, 2025 | prnewswire.comVolitionRx Limited (NYSE:VNRX) Director Acquires $50,000.00 in StockAugust 7, 2025 | insidertrades.comVolitionRx Announces Pricing of $1.2 Million Registered Direct OfferingAugust 4, 2025 | prnewswire.comNu.Q® Discover Expands Global Adoption and Epigenetic InnovationJuly 16, 2025 | prnewswire.comVolitionRx Limited (VNRX) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comVolition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of NucleosomesJuly 8, 2025 | prnewswire.comVolition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ FailureJune 12, 2025 | prnewswire.comJones Trading Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationJune 11, 2025 | msn.comVolitionRx director Guy Innes buys $10,772 in common stockJune 5, 2025 | investing.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of StockJune 5, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNRX, RNAC, CADL, and AVIR Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$3.14 -0.03 (-0.79%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Candel Therapeutics NASDAQ:CADL$4.86 -0.11 (-2.29%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Cartesian Therapeutics NASDAQ:RNAC$9.96 -0.14 (-1.34%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.VolitionRx NYSE:VNRX$0.64 +0.00 (+0.63%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
